Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Herpes-Based cancer therapy under safety watch: no major spread found

NCT ID NCT02910557

Knowledge-focused Sponsor: Amgen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study followed 187 melanoma patients treated with IMLYGIC, a modified herpes virus that attacks cancer cells. Researchers tracked whether the virus spread to patients' close contacts or healthcare providers, and monitored long-term safety for up to 5 years. The goal was to understand real-world risks of herpetic infection from this therapy.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Talimogene laherparepvec (T-VEC), a modified herpes virus therapy
What this could lead to
If successful, this study could confirm that IMLYGIC is safe for patients and does not easily spread to others, supporting its continued use in melanoma treatment.
What could go wrong
This is an observational study, not a test of effectiveness. It only tracks safety in a small group (187 patients) and cannot prove the therapy works better than other options.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

187 people

The number who actually took part.

Started

Aug 2017

Finished

Jan 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This postmarketing prospective cohort study will follow melanoma patients for up to 5 years after the first IMLYGIC dose in clinical practice. There is no experimental intervention, and the study population will receive standard-of-care treatment as determined by their treating physician.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient has provided written informed consent * Patient is an adult (≥ 18 years of age at the time of informed consent) with a diagnosis of melanoma * Patient enrolled within 1 month of receiving the first dose of IMLYGIC for the treatment of melanoma Exclusion Criteria: \- Patient has a prior history of being a subject in an interventional clinical trial for IMLYGIC

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Herpetic infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Herpesviridae infectious disease melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Herpetic infection Melanoma

Contacts and locations

Locations

  • Allegheny Health Network

    Pittsburgh, Pennsylvania, 15224, United States

  • Cheltenham General Hospital

    Cheltenham, GL53 7AN, United Kingdom

  • Churchill Hospital

    Oxford, OX3 7LJ, United Kingdom

  • Corazon United States of America, LLC doing business as Life Clinical Trials

    Coral Springs, Florida, 33076, United States

  • Guys Hospital

    London, SE1 9RT, United Kingdom

  • Intermountain Medical Center

    Murray, Utah, 84107, United States

  • Jefferson City Medical Group PC

    Jefferson City, Missouri, 65109, United States

  • Kantonsspital Graubuenden

    Chur, 7000, Switzerland

  • Landeskrankenhaus Salzburg

    Salzburg, 5020, Austria

  • Medizinische Universitaet Graz

    Graz, 8036, Austria

  • Mercy Medical Center

    Baltimore, Maryland, 21202, United States

  • Musgrove Park Hospital

    Taunton, TA1 5DA, United Kingdom

  • Ordensklinikum Linz Elisabethinen

    Linz, 4020, Austria

  • Rambam Medical Center

    Haifa, 3109601, Israel

  • Royal Marsden Hospital

    London, SW3 6JJ, United Kingdom

  • Sheba Medical Center

    Ramat Gan, 5262000, Israel

  • TriHealth Cancer Institute - Kenwood

    Cincinnati, Ohio, 45242, United States

  • Universitaetsklinikum Sankt Poelten

    Sankt Pölten, 3100, Austria

  • Universitaetsspital Basel

    Basel, 4052, Switzerland

  • Universitaetsspital Zuerich

    Zuerich Flughafen, 8058, Switzerland

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania, 15213, United States

  • University of Tennessee Medical Center

    Knoxville, Tennessee, 37920, United States

  • University of Wisconsin Hospital and Clinics

    Madison, Wisconsin, 53792, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.